Analyst Price Targets — RXRX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 17, 2025 7:14 am | — | Morgan Stanley | $11.00 | $4.20 | StreetInsider | JPMorgan Upgrades Recursion Pharmaceuticals (RXRX ) to Overweight |
| December 17, 2025 7:14 am | — | UBS | $11.00 | $4.20 | StreetInsider | JPMorgan Upgrades Recursion Pharmaceuticals (RXRX ) to Overweight |
| February 28, 2025 4:20 pm | — | Leerink Partners | $6.00 | $7.51 | TheFly | Recursion Pharmaceuticals price target lowered to $6 from $7 at Leerink |
| September 4, 2024 7:10 am | Gil Blum | Needham | $11.00 | $6.10 | StreetInsider | Recursion Pharmaceuticals (RXRX) PT Lowered to $11 at Needham |
| September 3, 2024 3:00 pm | Scott Schoenhaus | KeyBanc | $12.00 | $6.07 | StreetInsider | KeyBanc Reiterates Overweight Rating on Recursion Pharmaceuticals (RXRX ) |
| September 3, 2024 11:23 am | Dennis Ding | Jefferies | $6.00 | $6.02 | TheFly | Recursion Pharmaceuticals price target lowered to $6 from $8 at Jefferies |
| June 26, 2024 8:59 am | Scott Schoenhaus | KeyBanc | $16.00 | $8.76 | StreetInsider | KeyBanc Reiterates Overweight Rating on Recursion Pharmaceuticals (RXRX ) |
Latest News for RXRX
Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.53 per share a year ago.
Recursion Pharmaceuticals, Inc. (RXRX) Q4 2025 Earnings Call Transcript
Recursion Pharmaceuticals stock up on narrower Q4 loss as revenues jump on Roche milestone, beating estimates and boosting cash runway into 2028.
SALT LAKE CITY, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and financial results for its fourth quarter and full year ending December 31, 2025.
IRWD, RXRX, NVAX, VTRS and NTLA gear up for earnings as the Medical sector posts solid sales growth despite a slight profit dip so far.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for RXRX.
U.S. House Trading
No House trades found for RXRX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.